Kyverna Therapeutics Inc.

KYTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.12

-$0.01 (-0.14%)

At close: Sep 21, 2026, 4:00 PM ET

$7.07

-$0.05 (-0.64%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.14%

(1D)

Rating

Updated: Sep 12, 2026

11.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $432.86M

1D Range

6.99 7.18

52W Range

5.27 13.67

Valuation (TTM)

PE -2.42

PB 2.61

EV/EBITDA -1.62

Valuation (NTM)

Forward PE N/A

Forward PEG -0.25

Price Target $25

Cash Flow

FCF Yield -36.8%

SBC Adj. FCF Yield -39.6%

SBC Impact -7.6%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -5.0% | N/A

FCF 3Y | 5Y -30.5% | N/A

Returns

ROA -69.4%

ROE -81.9%

ROIC -80.0%

Financial Health

Net Cash

$191.31M

Current Ratio 9.06

Interest Coverage -88.69

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous...

Sector Healthcare

Industry Biotechnology

Employees 149

IPO Date Feb 8, 2024

Website kyvernatx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$25

Upside

+251.12%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞